ExThera Medical

ExThera Medical is a privately held medical device company that develops and commercializes extracorporeal blood filtration devices. The company's flagship product is the Seraph® 100 Microbind® Affinity Blood Filter, a groundbreaking device designed to remove pathogens and toxins from the bloodstream. This technology has demonstrated life-saving capabilities in a wide range of critically ill patients, particularly those suffering from sepsis and COVID-19. ExThera Medical is committed to advancing the use of blood purification therapies for both infectious diseases and other medical conditions, such as cancer, where removing harmful substances from the bloodstream could improve outcomes.

ExThera Medical is driven by a team of accomplished professionals with decades of experience in blood-contacting devices and biomaterials. The company has strong patent protection and a growing body of data from independent laboratory studies, participation in the DARPA Dialysis-Like Therapeutics program, and successful clinical use in both the US and EU. ExThera Medical is well-positioned to serve healthcare professionals and patients alike, offering a promising solution to address a variety of medical challenges with its innovative blood filtration devices.

ExThera Medical is a developer and commercializer of extracorporeal blood filtration devices, with a focus on pathogen and oncologic therapies. Their mission is to develop life-saving treatments for critically ill patients suffering from severe infections and cancer. They achieve this by utilizing their proprietary Microbind Affinity Blood Filter technology, which removes a broad range of harmful substances from the bloodstream, including pathogens and circulating tumor cells. ExThera's innovative products have demonstrated success in treating sepsis, COVID-19, and various other bloodstream infections, and their ONCObind™ procedure holds promise for treating metastatic cancer patients.

ExThera Medical promotes a culture of innovation and collaboration, fueled by a shared passion for developing life-saving therapies. The company fosters a collaborative environment that encourages the exchange of ideas and expertise among its employees, while also valuing individual contributions and promoting professional growth. Their commitment to scientific excellence is evident in their strong patent protection and growing body of data from independent laboratory studies, clinical trials, and participation in DARPA's Dialysis-Like Therapeutics program.